DOI: 10.1093/cid/ciag392 ISSN: 1058-4838
Virologic Outcomes After LA ART Initiation with and without Viremia in Two Large U.S. Clinic Cohorts
Matthew Spinelli, Megan J Heise, David V Glidden, Janet Grochowski, Jon Oskarsson, Larisa Niles-Carnes, Eudiah Ochieng, Meredith Lora, Amalia Aldredge, Nathanael Gistand, Chesa Cox, Jonathan A Colasanti, Monica Gandhi, Lauren F CollinsAbstract
Long-acting cabotegravir/rilpivirine supports virologic suppression among people with HIV (PWH) facing adherence challenges. In two large U.S. cohorts(n=1,070), 96% of viremic PWH achieved virologic suppression at a 4-week median. However, blips/failure were more frequent among PWH initiating with viremia, underscoring the need for careful monitoring and optimization of long-acting treatment.